Meningitis News and Research

Latest Meningitis News and Research

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

Pfizer's Prevnar 7 vaccine, which protects against pneumonia and meningitis, has been shown to reduce the risk of recurrent pneumococcal infection in patients living with HIV in Malawi, according to a study published Thursday in the New England Journal of Medicine, Reuters reports.

5 Mar 2010

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Majority of PI patients can be switched to IgPro20 without dose adjustment

Data from a European multicenter (non-IND study) showing that patients with PI who switched to IgPro20 from previously available SCIg formulations achieved comparable IgG trough levels without dosage adjustment, resulting in significantly less administration volume. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, US.

3 Mar 2010

IgPro20 protects PI patients against infection

Data presented today suggest that 20 percent liquid formulation, Immune Globulin Subcutaneous (Human) (SCIg), or IgPro20 effectively protects patients with primary immunodeficiencies (PI) against infection. The 20 percent formulation, the highest Ig concentration currently available, was also shown to sustain serum IgG levels without causing unexpected rates of adverse events. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, US.

2 Mar 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.

23 Feb 2010

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately RMB120 million ($17.6 million), which will be financed from working capital. The initial payment of RMB56.5 million ($8.3 million) will be paid before February 20, 2010 and the balance of the purchase price will be paid in three installments within three years.

16 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

$1.2B needed to aid women, children in 28 countries 'in crisis,' UNICEF says

UNICEF on Thursday launched a $1.2 billion appeal aimed at providing "life saving emergency assistance to millions of children and women in dire need," VOA News reports (Schlein, 2/4). "The appeal is part of UNICEF's Humanitarian Action Report 2010, released in Geneva ... which spotlights the desperate situation of children and women in 28 countries and territories facing deep humanitarian crises," the U.N. News Centre writes (2/4).

6 Feb 2010

Hockey player teams with Ottawa medical expert to raise awareness about meningococcal meningitis

When hockey fans converge at this Sunday's Ottawa 67's game, Garry Galley, former NHL defenseman and current analyst of Hockey Night in Canada, will team up with Dr. Gary Garber to share defense tips about the four vaccine-preventable strains of meningococcal meningitis with hockey enthusiasts at the Take a Shot for Meningitis Awareness booth. The pair will educate hockey enthusiasts and their families about meningococcal meningitis prevention and protection.

5 Feb 2010

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Providing preventive Tamiflu and educating and emphasizing the need for repeated hand sanitizer use and disinfectant spray helped stop the spread of H1N1 influenza at a boys' summer camp in northern Alabama, according the co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

4 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

Study indicates dogs make excellent models for studying human genetic disorders

In the new Swedish-Finnish study, published in Nature Genetics, the researchers identified five loci that predispose to an SLE-related disease in Nova Scotia duck tolling retrievers.

31 Jan 2010

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).

30 Jan 2010

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries.

29 Jan 2010

Sinovac prices public offering at $5.75 per common share

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today that it has priced its public offering of 10,000,000 common shares at $5.75 per common share. Sinovac has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,500,000 common shares on the same terms and conditions.

28 Jan 2010

Scientists map origin of MRSA, technology could help understanding of other diseases

"Scientists have found a way to track minutely-differing strains of the 'superbug' MRSA [methicillin-resistant Staphylococcus aureus] as they spread between people and across the globe, a finding that could aid efforts to control the deadly bacteria," Reuters/ABC News reports (Kelland, 1/21).

23 Jan 2010

Meningitis News and Research

Latest Meningitis News and Research

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

FDA approves CSL Behring's Hizentra for PI

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Majority of PI patients can be switched to IgPro20 without dose adjustment

IgPro20 protects PI patients against infection

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

$1.2B needed to aid women, children in 28 countries 'in crisis,' UNICEF says

Hockey player teams with Ottawa medical expert to raise awareness about meningococcal meningitis

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

FDA and PATH collaborate to advance pneumococcal vaccine development for children

WHO pneumonia expert honored with PACE Global Leadership Award

Study indicates dogs make excellent models for studying human genetic disorders

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Sinovac prices public offering at $5.75 per common share

Scientists map origin of MRSA, technology could help understanding of other diseases

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Meningitis News and Research

Latest Meningitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in